Advertisement
Screener

Kailera Therapeutics, Inc. (KLRA) Interest Income (Expense), Nonoperating, Net

2.8 / 5 stars · 68/120 Roast Me

Kailera Therapeutics, Inc. Interest Income (Expense), Nonoperating, Net

Kailera Therapeutics, Inc. (KLRA) reported Interest Income (Expense), Nonoperating, Net of $9.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Income Statement › Other Income

us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-12

  • Kailera Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $9.99M, a 370.08% increase year-over-year.
  • Kailera Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $5.72M, a 241.25% increase year-over-year.
  • Kailera Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-06-30 was $2.13M.
  • Kailera Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-03-31 was $1.68M.
Period endInterest Income (Expense), Nonoperating, Net 3 monthInterest Income (Expense), Nonoperating, Net 6 month
2026-06-30$9.99M
10-Q · filed 2026-08-12
$15.71M
10-Q · filed 2026-08-12
2026-03-31$5.72M
10-Q · filed 2026-05-26
2025-06-30$2.13M
10-Q · filed 2026-08-12
$3.80M
10-Q · filed 2026-08-12
2025-03-31$1.68M
10-Q · filed 2026-05-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Rapport Therapeutics, Inc. (RAPP)United States$1.623B-14.56
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Ultragenyx Pharmaceutical Inc. (RARE)United States$1.456B-5.62
OMEROS CORP (OMER)United States$1.456B5.50
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74